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Abstract 
 
Aging is associated with far-reaching changes in physiological functions 
resulting in morbidity and ultimately death. Age-related frailty, insecurity and 
reduced physical activity contribute to a progressive loss of muscle mass and 
function, commonly referred to as sarcopenia. Due to the increase in life 
expectancy in many countries, loss of muscle mass and its consequences 
gain in relevance for public health. At the same time, the molecular 
mechanisms that underlie sarcopenia are poorly understood and therefore, 
therapeutic approaches are limited. Interestingly though, endurance, strength 
and stretching exercise is significantly superior to all known pharmacological, 
nutritional and hormonal interventions for stabilizing, alleviating and reversing 
sarcopenia. Thus, increased knowledge about the plastic changes of skeletal 
muscle after physical activity and the signaling factors that mediate the 
beneficial effects of exercise on other organs might yield a better 
understanding of the disease and open new avenues for treatment. Here, we 
discuss how current discoveries about the peroxisome proliferator-activated 
receptor  coactivator 1 (PGC-1), a key exercise factor in muscle, and 
myokines, factors produced and secreted by active muscle fibers, expand our 
view of the pathological changes and the therapeutic options for sarcopenia. 
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Introduction 
 
Improved public health, nutrition, education and medical care culminated in a 
dramatic increase in life expectancy in many industrialized countries [1]. As a 
consequence, the drastically higher proportion of elderly individuals evokes 
new socioeconomic and public health problems.  
Senescence is characterized by a progressive decline in physiological 
functions of all organs, ultimately resulting in morbidity and death [1]. Loss of 
independence and the necessity of care are caused by mental and physical 
decline. One important factor is the decrease in mobility due to the age-
related reduction in muscle mass and function, collectively referred to as 
sarcopenia [2-5]. Socially, reduced mobility often results in a diminished ability 
of performing daily tasks and social interactions. Physically, loss of muscle 
mass greatly increases co-morbidities, mortality and thereby reduces life 
expectancy [6]. Regardless of gender, ethnicity and other factors, between 1 
and 2% of muscle mass per year are lost in individuals from the fourth decade 
on [6,7]. Furthermore, this rate accelerates after the age of 65 [6,7]. While 
sarcopenia per se seems inevitable, the question about the possibilities for 
slowing or reversal of this process arises. 
 
Causes and treatment of sarcopenia 
 
Many different factors and pathways have been implicated in the etiology of 
sarcopenia (Fig. 1). However, the relevance and relative importance of these 
potential causes are largely unknown. Furthermore, some of these 
 - 5 - 
observations are controversial, e.g. the preferential loss of glycolytic, fast-
twitch type II muscle fibers in sarcopenia, and might depend on individual 
context, study population or even species [8]. The details about these 
postulated mechanisms and a critical discussion of the relative relevance can 
be found in recent review articles (e.g. [2-4,6,8-11]). 
 
Muscle mass and fiber size are primarily determined by the balance between 
protein biosynthesis and degradation. In addition, fiber repair and 
regeneration contribute to maintenance of muscle tissue. Both of these 
processes are impaired in the elderly. Satellite cells, the adult muscle stem 
cells that are recruited for fiber regeneration and hypertrophy, exhibit a 
reduced myogenic potential with aging [12]. This might be due to a decline in 
the number of muscle cell precursors and an augmented inability of these 
cells to respond to anabolic stimuli such as the insulin-like growth factor 1 
(IGF-1) accompanied by a decrease in the expression of myogenic regulatory 
factors involved in muscle cell maturation [13,14]. IGF-1 increases muscle 
mass and fiber hypertrophy by promoting anabolic processes, activation of 
satellite cells and their subsequent fusion with muscle fibers [15]. During 
senescence, decreased growth hormone levels and the resulting reduction in 
IGF-1 signaling contribute to the failure to sustain muscle mass. Thus, 
modulation of the growth hormone/IGF-1 axis has been proposed as a 
therapeutic strategy to combat sarcopenia [16]. 
Muscle protein synthesis following food intake is reduced in sarcopenic 
muscle [17]. In fact, muscle tissue in the elderly seems less responsive to the 
anabolic effect of amino acids [17]. Accordingly, nutritional interventions 
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aiming at activating the mammalian target of rapamycin (mTOR) pathway and 
thereby increasing protein biosynthesis in muscle have limited effects in 
sarcopenia [17,18]. To make matters worse, dietary interventions with 
increased protein or caloric load can be counterproductive by exacerbating 
the gain of fat mass that is observed in many elderly individuals [6,17]. In 
contrast, and seemingly paradoxical, calorically restricted diets are potentially 
more efficacious against sarcopenia by promoting mitochondrial function and 
modulating apoptotic and autophagic pathways [2,19]. Caloric restriction and 
direct pharmacological interventions of the putative downstream mediators 
mTOR and sirtuin 1 (SIRT1) increase lifespan in a number of different 
organisms, including mammals [20,21]. However, some of the 
pharmacological interventions have limited effects on “healthspan”, i.e. the 
number of healthy years, or produce unwanted side effects as observed in 
mice treated with rapamycin, an mTOR inhibitor, which despite an increased 
lifespan had a higher incidence of cancer and cardiovascular disease [20]. 
Furthermore, caloric restriction could be hazardous for certain populations by 
promoting anemia, neurological deficits, edema, weakness, dizziness, 
lethargy and irritability [22]. 
 
Exercise as a therapeutic option for sarcopenia 
 
The best therapeutic option against sarcopenia currently is exercise, which 
promotes gain of muscle mass and function [9,17,23]. Moreover, physical 
activity improves neuromuscular adaptation, reduces inflammation and 
enhances fiber strength and endurance, all of which are beneficial for 
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sarcopenia patients. Accordingly, resistance-type and endurance exercise 
effectively improve muscle functionality in the elderly [17]. These training 
paradigms trigger specific adaptations in muscle fibers: resistance exercise 
promotes protein biosynthesis and hypertrophy of type IIx/b, glycolytic, fast-
twitch fibers. In contrast, endurance training increases mitochondrial function 
and oxidative metabolism by selective activation of type I and type IIa, 
oxidative, slow-twitch, high endurance fibers [24]. However, in all fibers, 
disuse results in a shift towards protein degradation and fiber atrophy. 
 
PGC-1: a key regulator of trained muscle 
 
Our knowledge of the molecular mechanisms that regulate training adaptation 
in muscle is rudimentary. Calcium signaling seems important for resistance 
and endurance training while additional signaling pathways such as those 
induced by growth factors are involved in the specification of the adaptive 
response [25]. Interestingly though, in the endurance trained muscle, most 
signaling pathways that are activated subsequent to motor neuron activity, 
mechanical stress and altered nutrient and energy state converge on the 
peroxisome proliferator-activated receptor  coactivator 1 (PGC-1) by either 
inducing PPARGC1A gene expression or posttranslationally modifying the 
PGC-1 protein [26-31]. PGC-1 is a transcriptional coactivator that binds to 
a number of transcription factors and thereby potently induces gene 
expression [26-30]. PGC-1 is detected in all oxidative tissues and is a strong 
promoter of mitochondrial biogenesis and function [26-30]. In addition, PGC-
1 regulates gene expression in a tissue-specific way. For example, PGC-1 
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is essential for fasting-induced hepatic gluconeogenesis, cold-induced 
thermogenesis in brown adipose tissue and increased output of the working 
heart [32-34]. In all of these tissues, PGC-1 activity is strongly regulated on 
the transcriptional and posttranslational level. Once activated in skeletal 
muscle, PGC-1 in turn controls many if not all of the adaptations of muscle 
fibers to endurance training [35-37]. Accordingly, mice with ectopically 
expressed PGC-1 in skeletal muscle exhibit fatigue-resistant muscle fibers 
and an improved endurance capacity [37,38]. In contrast, animals lacking a 
functional PPARGC1A gene in skeletal muscle experience an impaired ability 
to exercise and show a number of signs that define a pathologically inactive 
muscle [35,36]. 
 
Myokines as mediators of proximal and distal effects of exercise 
 
Repeated bouts of exercise affect almost every organ in our body and a 
sedentary lifestyle is an independent and strong risk factor for many chronic 
diseases [27,39]. However, it is unclear how physiological processes in distal 
organs are modulated by trained muscle. About 10 years ago, a better 
understanding of this organ crosstalk was obtained by the discovery of 
hormonal factors that are produced and secreted by active muscle fibers [40-
42]. Analogous to the adipokines, cytokines and other factors secreted from 
adipose tissue, muscle-derived proteins are called myokines [41,42]. The first 
muscle-derived secreted protein to be described was the cytokine interleukin 
6 (IL-6). Today, it is clear that many additional signaling molecules are 
produced by contracting muscle fibers and the current list of myokines 
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includes IL-6, IL-8, IL-15, brain derived neurotrophic factor (BDNF), leukemia 
inhibitory factor (LIF), follistatin-like 1 and fibroblast growth factor-21 (FGF21) 
[41-43].  
The plasma levels of other cytokines, including tumor necrosis factor  
(TNF), macrophage inflammatory protein 1 and 1 (MIP-1 and MIP-1), 
IL-1 receptor antagonist (IL-1ra) and IL-10, are also elevated after exercise. 
However, it is either unclear if these factors are produced by muscle or 
originate from immune cells or if these cytokines are the result of an 
inflammatory reaction since some of these cytokines are only observed after 
extremely strenuous exercise [44,45]. Therefore, none of these factors are 
currently classified as bona fide myokines. Similarly, an augmentation of IL-4 
and IL-13 was observed in human volunteers following strength training [46]. 
Further studies are needed to understand the role of these cytokines in the 
active muscle and to determine whether IL-4 and IL-13 are myokines. 
 
Myokines act in an auto-, para- or endocrine fashion and thereby have major 
implications on metabolic and other properties of muscle as well as distal 
organs (Fig. 2). For example, IL-6 induces glucose uptake and fatty acid -
oxidation in muscle, stimulates hepatic gluconeogenesis and induces lipolysis 
in fat [41]. Similarly, IL-15 seems to be involved in muscle-adipose tissue 
crosstalk [41]. High local IL-8 concentrations might be involved in exercise-
induced angiogenesis and hence increased capillarization of skeletal muscle 
[41]. BDNF augments fatty acid  oxidation in muscle and might contribute to 
the muscle-brain crosstalk in exercise [41,47]. 
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PGC-1 and myokines in sarcopenia 
 
PGC-1 expression levels are higher in type I and type IIa oxidative fibers 
compared to glycolytic fibers and in active vs. inactive muscle [37,48]. 
Accordingly, similar to other contexts of inadequate muscle activity, reduced 
PGC-1 gene expression is observed in skeletal muscle of aged rats [49] and 
in the elderly compared to young individuals, at least in some human 
populations [50]. This reduction correlates with the impaired oxidative capacity 
in sarcopenia [7,9]. Furthermore, loss-of-function studies of PGC-1 gene 
expression in murine skeletal muscle revealed a systemic, low-grade, chronic 
inflammation characterized by elevated circulating levels of IL-6 and TNF 
[35,36,51]. The levels of these two cytokines are likewise pathologically 
elevated in sarcopenia and are strongly associated with increased mortality in 
these individuals [52]. In contrast, the production of IL-6 and some of the other 
myokines is very transient during exercise followed by a rapid normalization to 
pre-exercised levels shortly after a training bout [41]. Thus, the reduction of 
PGC-1 transcription in an inactive muscle such as that in sarcopenia and the 
ensuing dysregulation of myokine production potentially contributes to the 
morbidity and mortality in this disease [27]. 
 
Therapeutic potential 
 
At the moment, it is unclear if the reduction of PGC-1 in sarcopenic muscle 
is a general phenomenon (e.g. see refs. [50,53] for studies with diametrically 
opposed conclusions about the association between PGC-1 expression and 
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age in human muscle) and whether the dysregulation is cause or 
consequence of the muscle wasting process in the elderly. In any case 
however, recent advances imply that a modulation of PGC-1 levels in 
muscle might be beneficial for sarcopenia patients. First, old rats with a 
blunted induction of PGC-1 expression subsequent to exercise are also 
resistant to exercise-mediated improvement of sarcopenia [54]. Second, 
ectopic expression of PGC-1 in skeletal muscle reduced muscle fiber 
damage, deterioration in innervation, and inflammation in old mice [55]. In 
addition, endurance capacity and survival of old muscle-specific PGC-1 
transgenic mice is increased compared to that of wild-type littermates [55]. 
Furthermore, similar gain-of-function studies in mouse models with muscle-
specific, transgenically expressed PGC-1 revealed an improvement of fiber 
integrity and muscle function in a variety of different muscle wasting contexts, 
including denervation-induced fiber atrophy, Duchenne muscular dystrophy, a 
mitochondrial myopathy and statin-mediated fiber damage [56-59]. The 
mechanisms by which PGC-1 improves these muscle diseases with 
completely different etiology are unknown. However, several of the postulated 
pathological mechanisms in sarcopenia could be rectified by PGC-1 
function, such as decreased mitochondrial function, impaired reactive oxygen 
species (ROS) detoxification, neuromuscular junction abnormalities or 
increased pro-inflammatory gene expression [27,30]. In general, like patients 
suffering from other muscle wasting diseases, elderly with sarcopenia would 
benefit from the ability of elevated PGC-1 to induce a trained muscle 
phenotype regardless of the actual level of physical activity [30,37,38,56]. 
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Conclusion and perspectives 
 
Pharmacological interventions aimed at increasing PGC-1 expression in 
muscle and at normalizing myokine production and secretion pattern would be 
promising new avenues for slowing down and reversing sarcopenia. 
Unfortunately, despite screening efforts, safe and chronically applicable 
compounds that robustly and selectively augment PGC-1 activity in muscle 
remain elusive [30,51]. Furthermore, drug-induced PGC-1 expression will 
have to be achieved within a physiological, therapeutically beneficial window 
since in excess, PGC-1 causes detrimental effects in muscle, heart and 
other tissues [30]. Similar to PGC-1, it is unclear how aberrant myokine 
levels can be normalized pharmacologically. Thus, more research on the 
upstream signaling and downstream effects of PGC-1 and myokines in 
muscle as well as distal tissues is needed. Until then, a healthy and active 
lifestyle as prevention, and exercise combined with nutritional and hormonal 
interventions as therapy remain the most promising weapons in the battle 
against sarcopenia and other ailments of old age. 
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Figure Legends 
 
Fig. 1. Potential causes and pathophysiological consequences of 
sarcopenia. Age-related changes in physiological properties and social 
behavior favor molecular adaptations that could contribute to the causation 
and progression of sarcopenia. The resulting frailty, immobility and weakness 
further feed the vicious cycle and ultimately increase morbidity and mortality. 
 
Fig. 2. Myokine production and putative effects on muscle and distal 
organs. Myokines are produced and secreted by skeletal muscle and exert 
subsequent auto-, para- and endocrine effects. Physical activity (through 
PGC-1?) and an inactive lifestyle as observed in sarcopenia control the 
production of myokines. Abbreviations: FA, fatty acid. 
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